Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Samuel Colella Insider Profile
4 Followers
Samuel Colella, Director at Flexion Therapeutics, holds 0.00 shares in Flexion Therapeutics (Ticker: FLXN), holds 239.27K shares in Standard BioTools (Ticker: LAB), holds 1.57M shares in Jazz Pharmaceuticals (Ticker: JAZZ).
Profitable Transactions
17 out of 19 Profitable Transactions
Average Return
+37.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Samuel Colella holds in companies
Most Profitable Insider Trade
The most profitable trade made by Samuel Colella
Samuel Colella's Trading History
Flexion Therapeutics
Nov 19, 2021
―
Uninformative Sell
12.72M
$0.00
Standard BioTools
Mar 12, 2020
Director
Informative Buy
54.20K
$612.53K
Jazz Pharmaceuticals
Jan 13, 2012
Director
Uninformative Sell
809.34K
$172.02M
Insulet
―
Former 10% Owner
―
$14.95M
Genomic Health
Oct 03, 2014
―
Uninformative Buy
9.99K
$3.78M
Alexza Pharmaceuticals
Jan 28, 2010
―
Uninformative Buy
―
$242.03K
Veracyte
Nov 04, 2013
Director, Ten Percent Owner
Uninformative Buy
―
$421.03K
Solta Medical Inc
―
―
―
―
List of latest transactions for each holding click on a transaction to see Samuel Colella's performance on stock
You May Also Like
Samuel Colella insider profile FAQ
What is the percentage of profitable transactions made by Samuel Colella?
The percentage of profitable transactions made by Samuel Colella is 89%.
What is the average return per transaction made by Samuel Colella?
The average return per transaction made by Samuel Colella is 37.60%.
What stocks does Samuel Colella hold?
Samuel Colella holds: FLXN, LAB, JAZZ, PODD, GHDX, ALXA, VCYT, SLTM stocks.
What was Samuel Colella’s latest transaction?
Samuel Colella latest transaction was an Uninformative Sell of $12.72M.
What was Samuel Colella's most profitable transaction?
Samuel Colella’s most profitable transaction was an Informative Buy of LAB stock on August 8, 2017. The return on the trade was 117.70%.
What is Samuel Colella's role in Flexion Therapeutics?
Samuel Colella's role in Flexion Therapeutics is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.